Skip to main content
Menu

H1 FY25 shareholder update

18 June 2025

Oliver Bedford, Lucy Bloomfield, Archie Stirling and Anna Salim from the VCT’s fund management team review the six months to 31 March 2025, including an update on markets, the macroeconomic backdrop, investment activity and the VCT’s performance.

Important for shareholders

Our last cheque payment for dividends will be in July 2025. If you currently receive dividends by cheque, please provide your bank details before the next payment due in February 2026. You can update your details by contacting Equiniti on 0371 384 2030 or via the Shareview website.

Shareview online

Contact us

For all shareholder enquiries including valuations, dividend payments or transactions, please contact the admin team:

Call us +44 (0)1253 376 622
Email aimvct@canaccord.com

For further information about the VCT or its underlying investments, please contact the fund management team on +44 (0)207 523 4837 or send us a message.

Existing shareholder?

Please indicate below if you would like to receive the following communications by email. You can withdraw your consent at any time by clicking on the unsubscribe option in any email you receive or by emailing aimvct@canaccord.com.

Marketing communications and factsheets - I would like to receive offer updates, information about future fundraises, factsheets and other related marketing communications by email from Hargreave Hale AIM VCT (all marketing communications are approved by Canaccord Genuity Wealth Limited).

Marketing communication and factsheets tick box *

Shareholder updates - I would like to receive regular shareholder updates and information on shareholder events from Hargreave Hale AIM VCT.

Shareholder updates tick box *

By selecting one or both of the options above, you consent to the sending of updates by email.

Investment involves risk and you may not get back what you invest. It’s not suitable for everyone.

Investment involves risk and you may not get back what you invest. It’s not suitable for everyone.